US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

1.430 +0.030 (+2.14%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.55% to 33,233.33 while the NASDAQ rose 0.87% to 12,962.92. The... 
Via Benzinga
Topics Economy Stocks
News headline image
US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected ↗
U.S. stocks traded mixed this morning, ahead of interest rate decision from the Federal Reserve. Following the market opening Wednesday, the Dow traded down 0.05% to 33,036.63 while the NASDAQ rose... 
Via Benzinga
Topics Economy Stocks
News headline image
Why Is WeWork (WE) Stock Down 38% Today? ↗
WeWork stock is falling on Wednesday as investors in WE shares react to reports that the company is considering a bankruptcy filing. 
Via InvestorPlace
Topics Bankruptcy
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Recap: Cellectis Q1 Earnings ↗
 
Via Benzinga
News headline image
Why Is Paycom Software (PAYC) Stock Down 39% Today? ↗
Paycom Software stock is falling hard on Wednesday as investors in PAYC go over the company's mixed earnings report for Q3 2023! 
Via InvestorPlace
News headline image
Why Is Mainz Biomed (MYNZ) Stock Moving Today? ↗
Mainz Biomed stock is on the move Wednesday as investors in MYNZ react to results from a colorectal cancer screening test campaign. 
Via InvestorPlace
News headline image
Why Is Cellectis (CLLS) Stock Up 175% Today? ↗
Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment from AstraZeneca. 
Via InvestorPlace
News headline image
Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today! 
Via InvestorPlace
News headline image
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
BALLI-01 (evaluating UCART22) abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL population 
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >